GE Healthcare: UBS now a seller

(CercleFinance.com) - The analyst downgrades his opinion on the stock to Sell (from Neutral), with a target price cut to E74 (from E84), which represents 20% downside potential.


UBS believes that earnings are taken into account but risks are not.

GE Healthcare's medium-term margin forecasts are exaggerated and the risks relating to China are significant. Forecasts are reduced to 3%-6% below consensus, UBS says.

GE Healthcare has confirmed its annual adjusted EPS target range of $4.20-$4.35, and has raised adjusted EBIT margin forecast to 15.7%-16%, but has reduced organic revenue growth expectations to +1%-2%, due to headwinds in China.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.